Predictors of participant retention in two chemoprevention feasibility trials

被引:8
作者
Bowen, DJ
Cartmel, B
Barnett, M
Goodman, G
Omenn, GS
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Yale Univ, New Haven, CT 06520 USA
关键词
D O I
10.1007/BF02884835
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Retention of participants for intervention and follow-lip activities is critical in cancer chemoprevention trials. Little has been published about retention patterns and predictors of retention in prevention studies. The Carotene and Retinol Efficacy Trial (CARET) provides an opportunity to study retention of volunteer participants in a large, long-term clinical trial. Two pilot studies were conducted in different populations to test the feasibility of critical strategies for the long-term study. Thirteen pel cent of the asbestos-exposed workers and 18% of the smokers became inactive during the pilot study! Of those remaining active, all bur 2% of asbestos-exposed workers pilot study participants and 5% of smokers pilot study participants chose to participate in the full-scale efficacy trial. Five baseline predictors of inactivity for the asbestos-exposed participants emerged: being non-White, being a current smoker; having a history of high blood pressure at baseline,,reporting two or more increases in symptoms during the placebo run-in, and having higher baseline levels of negative mental health measures (i.e. anxiety, depression, and fatigue). The only significant predictor of inactivity for smoker pilot participants was reporting symptoms during the placebo run-in. The most frequently reported reasons for becoming inactive during the pilot studies were general health issues and problems and symptoms that were seen as specific to the CARET vitamins. These findings suggest areas that could be tested to optimize retention in clinical trials.
引用
收藏
页码:210 / 215
页数:6
相关论文
共 11 条
[1]  
GOODMAN GE, 1993, CANCER EPIDEM BIOMAR, V2, P389
[2]  
Karnofsky DA., 1949, CLIN EVALUATION CHEM, P196
[3]  
Meichenbaum D., 1987, FACILITATING TREATME
[4]  
Meinert C. L., 1986, CLIN TRIALS DESIGN C
[5]  
MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO
[6]  
2-W
[7]   Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial [J].
Omenn, GS ;
Goodman, GE ;
Thornquist, MD ;
Balmes, J ;
Cullen, MR ;
Glass, A ;
Keogh, JP ;
Meyskens, FL ;
Valanis, B ;
Williams, JH ;
Barnhart, S ;
Cherniack, MG ;
Brodkin, CA ;
Hammar, S .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1550-1559
[8]  
OMENN GS, 1994, CANCER RES, V54, pS2038
[9]   Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease [J].
Omenn, GS ;
Goodman, GE ;
Thornquist, MD ;
Balmes, J ;
Cullen, MR ;
Glass, A ;
Keogh, JP ;
Meyskens, FL ;
Valanis, B ;
Williams, JH ;
Barnhart, S ;
Hammar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (18) :1150-1155
[10]  
OMENN GS, 1993, CANCER EPIDEM BIOMAR, V2, P381